PALL, GELMAN SCIENCES $284 MIL. MERGER IS "MORE FAVORABLE" THAN PREVIOUS PACT WITH MEMTEC, GELMAN SAYS; DEAL BOLSTERS PALL'S LABORATORY PRODUCT OFFERINGS
This article was originally published in The Gray Sheet
Microfiltration products firms Pall and Gelman Sciences took advantage of an escape clause in Gelman's merger deal with Memtec Ltd., announcing Oct. 28 a definitive agreement to merge in a stock transaction valued at $284 mil., or $33 per Gelman share.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.